All orders placed by 2pm EST will be shipped same day Free Shipping Over $150 Gift With Every Order All orders placed by 2pm EST will be shipped same day Free Shipping Over $150 Gift With Every Order

CJC-1295 (No DAC)

Categories:

CJC-1295 (No DAC) is a synthetic peptide designed for research use only in laboratory settings. This compound is a modified analog of the original CJC-1295, lacking diacetylcystamine (DAC) modifications, which may affect its pharmacokinetic profile. For research use only.

Price range: $41.00 through $67.00

ℹ️ RESEARCH USE ONLY

For research purposes only. Not for human or animal use & not FDA-approved. By purchasing, you confirm you are 21 or older and qualified researcher

CJC-1295 (No DAC)

CJC-1295 is a synthetic peptide designed to mimic the properties of the endogenous growth hormone-releasing hormone (GHRH) analog, previously used in veterinary medicine for its growth-promoting effects. This peptide variant, devoid of the diacetylated amino terminus (DAC), represents a modification for specific research applications related to hormone signaling and biological responses.

Research Context

CJC-1295 has been historically explored in veterinary and preclinical studies for its potential in enhancing growth performance in livestock. The removal of the DAC modification can alter peptide stability, receptor binding affinity, and biological activity in different experimental contexts. In research settings, CJC-1295 is often employed to study the mechanisms of growth hormone secretion, tissue-specific responses, and comparative pharmacokinetic profiles.

Research Overview

CJC-1295 (no DAC) serves as a research tool to investigate the role of growth hormone-releasing hormone analogs in mammalian systems. Its primary relevance lies in preclinical evaluations, where researchers assess its impact on endocrine function, metabolic processes, and physiological adaptations. The absence of DAC may influence receptor interaction dynamics, allowing for targeted experimentation in studies examining peptide modifications and their effects on hormone axis regulation.

Key Research Focus Areas

  • Endocrine Function Studies: Investigation of growth hormone secretion and pituitary responsiveness to CJC-1295 in comparative models.
  • Pharmacokinetic and Metabolic Analysis: Evaluation of peptide clearance, tissue distribution, and metabolic effects in experimental animals.
  • Comparative Binding Affinity: Assessment of receptor binding dynamics between DAC-modified and non-modified analogs.
  • Biological Response Variability: Analysis of tissue-specific responses (e.g., muscle, liver, adipose) to CJC-1295 exposure.
  • Peptide Stability and Modification Effects: Examination of structural stability and activity variations due to DAC removal.

This peptide is provided for academic and industrial research purposes only. Researchers should follow established protocols, ensure compliance with institutional review boards, and adhere to ethical guidelines applicable to their specific experimental designs.

For research use only. Not for human or animal consumption.

Size

10MG, 5MG

Reviews

There are no reviews yet.

Be the first to review “CJC-1295 (No DAC)”

Your email address will not be published. Required fields are marked *

CJC-1295 (No DAC)

CJC-1295 is a synthetic peptide designed to mimic the properties of the endogenous growth hormone-releasing hormone (GHRH) analog, previously used in veterinary medicine for its growth-promoting effects. This peptide variant, devoid of the diacetylated amino terminus (DAC), represents a modification for specific research applications related to hormone signaling and biological responses.

Research Context

CJC-1295 has been historically explored in veterinary and preclinical studies for its potential in enhancing growth performance in livestock. The removal of the DAC modification can alter peptide stability, receptor binding affinity, and biological activity in different experimental contexts. In research settings, CJC-1295 is often employed to study the mechanisms of growth hormone secretion, tissue-specific responses, and comparative pharmacokinetic profiles.

Research Overview

CJC-1295 (no DAC) serves as a research tool to investigate the role of growth hormone-releasing hormone analogs in mammalian systems. Its primary relevance lies in preclinical evaluations, where researchers assess its impact on endocrine function, metabolic processes, and physiological adaptations. The absence of DAC may influence receptor interaction dynamics, allowing for targeted experimentation in studies examining peptide modifications and their effects on hormone axis regulation.

Key Research Focus Areas

  • Endocrine Function Studies: Investigation of growth hormone secretion and pituitary responsiveness to CJC-1295 in comparative models.
  • Pharmacokinetic and Metabolic Analysis: Evaluation of peptide clearance, tissue distribution, and metabolic effects in experimental animals.
  • Comparative Binding Affinity: Assessment of receptor binding dynamics between DAC-modified and non-modified analogs.
  • Biological Response Variability: Analysis of tissue-specific responses (e.g., muscle, liver, adipose) to CJC-1295 exposure.
  • Peptide Stability and Modification Effects: Examination of structural stability and activity variations due to DAC removal.

This peptide is provided for academic and industrial research purposes only. Researchers should follow established protocols, ensure compliance with institutional review boards, and adhere to ethical guidelines applicable to their specific experimental designs.

For research use only. Not for human or animal consumption.

Related Products

Age Verification!

*By continuing, you confirm eligibility and legal compliance.